Search

Your search keyword '"MESH: B7-H1 Antigen"' showing total 8 results
Start Over Descriptor "MESH: B7-H1 Antigen" Topic 0302 clinical medicine
8 results on '"MESH: B7-H1 Antigen"'

1. PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua

Author

Emanuela Marcenaro, Marco Greppi, Enrico Munari, Paola Vacca, Maria Cristina Mingari, Alessandro Moretta, Silvia Pesce, Lorenzo Moretta, Ezio Fulcheri, Daniel Olive, Department of Experimental Medicine - DIMES [Genoa, Italy] (DIMES), University of Genoa (UNIGE), Department of Experimental Medicine, University of Genoa, D.I.C.M.I., Universita degli studi di Genova, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Istituto Nazionale per la Ricerca sul Cancro, Genova, Immunologia, Università di Genova, Dipartimento di Medicina Sperimentale, IRCCS Istituto Giannina Gaslini, Genova, and Università degli studi di Genova = University of Genoa (UniGe)

Subjects
MESH: Signal Transduction, 0301 basic medicine, MESH: Trophoblasts, [SDV]Life Sciences [q-bio], Programmed Cell Death 1 Receptor, B7-H1 Antigen, MESH: Decidua, Immune tolerance, MESH: Pregnancy, 0302 clinical medicine, Pregnancy, MESH: B7-H1 Antigen, Homeostasis, Innate, Immunology and Allergy, Lymphocytes, Receptor, Hepatitis A Virus Cellular Receptor 2, MESH: Cytokines, Innate lymphoid cell, Decidua, MESH: Programmed Cell Death 1 Receptor, Trophoblasts, MESH: Placental Circulation, 3. Good health, Cell biology, medicine.anatomical_structure, MESH: Homeostasis, Cytokines, Female, MESH: Immunity, Innate, Signal transduction, Signal Transduction, Programmed cell death, MESH: Immune Tolerance, T cell, Immunology, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Biology, 03 medical and health sciences, Immune system, Immune Tolerance, medicine, Humans, Placental Circulation, MESH: Humans, Immunity, Immunity, Innate, MESH: Hepatitis A Virus Cellular Receptor 2, 030104 developmental biology, MESH: Lymphocytes, MESH: Female, 030215 immunology
Abstract

International audience; Group 3 innate lymphoid cells (ILC3) have been detected in both murine and human decidual tissues where they are thought to play a relevant role in the induction and maintenance of pregnancy. However, limited information exists on the molecular mechanisms that regulate these cells, including immune checkpoints. Here, we show that ILC3 express the inhibitory checkpoints programmed cell death (PD-1) and T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) during the first trimester of pregnancy and that these receptors could regulate production of cytokines, including IL-22, IL-8, and TNF-α, induced by IL-23. We also show that the intermediate extravillous trophoblast (iEVT) expresses high levels of the PD-1-ligand PD-L1, suggesting that PD-1/PD-L1 interaction may regulate ILC3 function at the feto-maternal interface. Our present data provide the first evidence that human decidual ILC3 express a functional PD-1. It is possible that an altered expression or function of PD-1 may break the immune-tolerance resulting in pregnancy failure.

Published
2019

2. Soluble programmed death‐1 (sPD‐1) as predictor of early surgical outcomes of paediatric cystic echinococcosis

Author

Abdellatif Nouri, Bruno Gottstein, Laurence Millon, Amine Ksia, Anne-Pauline Bellanger, Eya Ben Salah, Rabeb Farhani, Hamouda Babba, Sana Mosbahi, Wahiba Sakly, Coralie Barrera, Laboratoire de Parasitologie-Mycologie Médicale et Moléculaire [Monastir, Tunisie] (LP3M-LR12ES08), Département de Biologie Clinique B [Monastir, Tunisie], Faculté de Pharmacie [Monastir] (FPHM)-Faculté de Pharmacie [Monastir] (FPHM), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Department of Paediatric Surgery and LR12SP13, CHU Fattouma Bourguiba [Monastir] (HFB), Institute for Infectious Diseases, Faculty of Medicine, University of Berne, 3001 Berne, Switzerland, Service de parasitologie et mycologie [CHRU de Besançon], and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
0301 basic medicine, Male, sPD-1, Gastroenterology, recP29, B7-H1 Antigen, 0302 clinical medicine, MESH: Child, Secondary Prevention, follow-up, MESH: B7-H1 Antigen, Prospective Studies, Surgical treatment, Prospective cohort study, Child, MESH: Treatment Outcome, biology, MESH: Secondary Prevention, MESH: Enzyme-Linked Immunosorbent Assay, 3. Good health, cystic echinococcosis, Treatment Outcome, Child, Preschool, Female, Antibody, medicine.medical_specialty, Adolescent, 030231 tropical medicine, Immunology, Enzyme-Linked Immunosorbent Assay, Relapse rate, post-surgical outcome, sPD-L1, 03 medical and health sciences, MESH: Echinococcosis, children, Echinococcosis, Internal medicine, mental disorders, medicine, Humans, MESH: Adolescent, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, MESH: Humans, Cystic echinococcosis, Significant difference, MESH: Child, Preschool, MESH: Prospective Studies, MESH: Male, 030104 developmental biology, biology.protein, MESH: Biomarkers, Parasitology, Programmed death 1, MESH: Female, Biomarkers
Abstract

Aims Following treatment, cystic echinococcosis (CE) exhibits a relatively high relapse rate. Here, we evaluated the value of soluble programmed death-1 (sPD-1), sPD-1 ligand (sPD-L1) and anti-recP29 antibody concentrations, as predictors of early surgical treatment outcome in young CE-affected patients. Methods and results This prospective study included 59 Tunisian children (177 plasmas ), where CE was surgically treated and monitored for 3 post-operative years. Based on CE post-surgical development, patients were clustered into a "No relapsed" CE (NRCE; n = 39) and a "Relapsed" CE (RCE; n = 20) group. Serum levels of sPD-1, sPD-L1 and anti-recP29 IgG were measured using ELISA. In the NRCE group, sPD-1, sPD-L1 and anti-recP29 IgG concentrations were significantly lower at D365 than at D30. By contrast, in the RCE group, no significant difference was observed between D0, D30 and D365.When considering individual variations, the probability to be "relapse-free" was 67% and 73% when anti-recP29 IgG and sPD-L1 level, respectively, decreased between D30 and D365. The probability to be "relapse-free" was 86% when the sPD-1 level decreased between D30 and D365 (p= 0.003; Chi-square test). Conclusion sPD-1 may be a useful biomaker for the early evaluation of surgical procedure efficacy in pediatric CE cases.

Published
2021

3. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

Author

Coralie Bloch-Queyrat, Florent Grange, Lydia Deschamps, Sandrine Mansard, Nicole Basset-Seguin, Annick Tibi, Vincent Levy, Sarah Guégan, D. Legoupil, Jean-Philippe Arnault, Henri Montaudié, Marouane Boubaya, Olivier Dereure, Yannick Le Corre, A. Stefan, François Aubin, Céline Alloux, Jean-Jacques Grob, Peter Petrow, Soufian Cherbal, Groupe de cancérologie cutanée, Philippe Saiag, Nicolas Meyer, Isabelle Lopez, Marie Beylot-Barry, Eve Maubec, Marie-Thérèse Leccia, Brigitte Dréno, Ouidad Zehou, Laurent Machet, Julie De Quatrebarbes, Sophie Dalac, Monica Dinulescu, E. Wierzbicka-Hainaut, Isabelle Scheer-Senyarich, Herrada, Anthony, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris 13 (UP13), Polyclinique Saint Côme, Institut Curie [Paris], CHU Bordeaux [Bordeaux], Hopital Saint-Louis [AP-HP] (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital de la Timone [CHU - APHM] (TIMONE), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Grenoble, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Ambroise Paré [AP-HP], Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Centre Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Clermont-Ferrand, Hôpital Cochin [AP-HP], CHU Amiens-Picardie, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Agence Générale des Equipements et Produits de Santé [Paris] (AGEPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, Time Factors, MESH: Immune Checkpoint Inhibitors, Cell, Phases of clinical research, Pembrolizumab, B7-H1 Antigen, Antineoplastic Agents, Immunological, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Progression-Free Survival, MESH: B7-H1 Antigen, Medicine, Immune Checkpoint Inhibitors, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH: Carcinoma, Squamous Cell, Middle Aged, Progression-Free Survival, 3. Good health, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Monoclonal, Carcinoma, Squamous Cell, Disease Progression, Female, MESH: Disease Progression, France, Adult, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Pharmacotherapy, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Carcinoma, Humans, Progression-free survival, Aged, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Time Factors, MESH: Quality of Life, MESH: Adult, medicine.disease, MESH: Antineoplastic Agents, Immunological, MESH: Male, Clinical trial, MESH: France, 030104 developmental biology, MESH: Antibodies, Monoclonal, Humanized, Quality of Life, business, MESH: Female
Abstract

PURPOSE To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs). PATIENTS AND METHODS Patients, predominantly men, with their CSSCs’ immunohistochemically determined programmed cell death-ligand 1 (PD-L1) status determined (tumor proportion score threshold, 1%), received pembrolizumab (200 mg every 3 weeks). The primary endpoint was the 39-patient primary cohort’s objective response rate at week 15 (ORRW15). Secondary objectives were best ORR, overall survival (OS), progression-free survival (PFS), duration of response (DOR), safety, ORR according to PD-L1 status and health-related quality of life using Functional Assessment of Cancer Therapy–General (FACT-G) score. An 18-patient expansion cohort, recruited to power the study to evaluate the ORRW15 difference between PD-L1+ and PD-L1– patients, was assessed for ORR, disease control rate, and safety, but not survival. RESULTS Median age of all patients was 79 years. The primary cohort’s ORRW15 was 41% (95% CI, 26% to 58%), including 13 partial and 3 complete responses. Best responses were 8 partial and 8 complete responses. At a median follow-up of 22.4 months, respective median PFS, DOR, and OS were 6.7 months, not reached, and 25.3 months, respectively. Pembrolizumab-related adverse events affected 71% of the patients, and 4 (7%) were grade ≥ 3. One death was related to rapid CSCC progression; another resulted from a fatal second aggressive head and neck squamous cell carcinoma diagnosed 15 weeks postinclusion. ORRW15 for the entire population was 42%; it was significantly higher for PD-L1+ patients (55%) versus PD-L1– patients (17%; P = .02). Responders’ W15 total FACT-G score had improved ( P = .025) compared with nonresponders. CONCLUSION First-line pembrolizumab monotherapy exhibited promising anti-CSCC activity, with durable responses and manageable safety. PD-L1 positivity appears to be predictive of pembrolizumab efficacy.

Published
2020

4. Targeting Glutamine Metabolism and PD-L1: A Novel Anti-tumor Pas de Deux

Author

Naomi Taylor, Valerie Dardalhon, Maria I. Matias, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Hematopoïèse et Immunothérapie, and Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)

Subjects
SERCA, Glutamine, Cell, Glutamine metabolism, MESH: NF-kappa B, [SDV.CAN]Life Sciences [q-bio]/Cancer, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Downregulation and upregulation, Immunity, PD-L1, Neoplasms, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], medicine, MESH: B7-H1 Antigen, Humans, MESH: Neoplasms, Molecular Biology, 030304 developmental biology, Antitumor activity, 0303 health sciences, MESH: Glutamine, MESH: Humans, biology, NF-kappa B, Cell Biology, 3. Good health, medicine.anatomical_structure, biology.protein, Cancer research, 030217 neurology & neurosurgery
Abstract

Refers toJun-Kyu Byun, Mihyang Park, Seunghyeong Lee, Jae Won Yun, Jaebon Lee, Jae Sun Kim, Sung Jin Cho, Hui-Jeon Jeon, In-Kyu Lee, Yeon-Kyung Choi, Keun-Gyu ParkInhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor ImmunityMolecular Cell, Volume 80, Issue 4, 19 November 2020, Pages 592-606.e8; International audience; In this issue of Molecular Cell, Byun et al. (2020) find that the dual targeting of glutamine metabolism and the PD-L1 checkpoint inhibitor augments anti-tumor immunity. Mechanistically, decreased glutamine availability attenuated S-glutathionylation of SERCA, resulting in an increase in cytosolic calcium, enhanced NF-κB activity, and upregulation of programmed death-ligand 1.

Published
2020

5. PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer

Author

Heskamp, Sandra, Wierstra, Peter, Molkenboer-Kuenen, Janneke, Sandker, Gerwin, Thordardottir, Soley, Cany, Jeannette, Olive, Daniel, BUSSINK, Johan, Boerman, Otto, Dolstra, Harry, Aarntzen, Erik, Hobo, Willemijn, Molkenboer-Kuenen, Janneke D.M., Aarntzen, Erik H.J.G., Radboud University Medical Center [Nijmegen], Biothérapies Hépatiques, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Department of Nuclear Medecine (Radboud University Medical Centre), Department of Laboratory Medicine, Radboud university [Nijmegen]-Nijmegen Centre for Molecular Life Sciences-Nijmegen Medical Centre [Nijmegen], Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Radboud University [Nijmegen]-Nijmegen Centre for Molecular Life Sciences-Nijmegen Medical Centre [Nijmegen]

Subjects
0301 basic medicine, Cancer Research, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], [SDV]Life Sciences [q-bio], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], B7-H1 Antigen, MESH: Antibodies, Monoclonal, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Neoplasms, MESH: B7-H1 Antigen, MESH: Animals, MESH: Neoplasms, MESH: Indium Radioisotopes, 0303 health sciences, Mice, Inbred BALB C, biology, Indium Radioisotopes, Antibodies, Monoclonal, Hematology, 3. Good health, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Pd l1 expression, Female, MESH: Single Photon Emission Computed Tomography Computed Tomography, Lymph, Antibody, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Single Photon Emission Computed Tomography Computed Tomography, MESH: Cell Line, Tumor, Immunology, MESH: Mice, Inbred BALB C, Spleen, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], 03 medical and health sciences, Immune system, Downregulation and upregulation, MESH: Mice, Inbred C57BL, PD-L1, Cell Line, Tumor, medicine, Animals, Humans, 030304 developmental biology, MESH: Humans, business.industry, Cancer, medicine.disease, Mice, Inbred C57BL, Disease Models, Animal, 030104 developmental biology, Humanized mouse, biology.protein, Cancer research, Ct imaging, MESH: Disease Models, Animal, business, Nanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19], MESH: Female
Abstract

Contains fulltext : 202258.pdf (Publisher’s version ) (Closed access) Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression in tumors seems to be a prerequisite for treatment response. However, PD-L1 is heterogeneously expressed within tumor lesions and may change upon disease progression and treatment. Imaging of PD-L1 could aid in patient selection. Previously, we showed the feasibility to image PD-L1(+) tumors in immunodeficient mice. However, PD-L1 is also expressed on immune cell subsets. Therefore, the aim of this study was to assess the potential of PD-L1 micro single-photon emission tomography/computed tomography (microSPECT/CT) using radiolabeled PD-L1 antibodies to (i) measure PD-L1 expression in two immunocompetent tumor models (syngeneic mice and humanized mice harboring PD-L1 expressing immune cells) and (ii) monitor therapy-induced changes in tumor PD-L1 expression. We showed that radiolabeled PD-L1 antibodies accumulated preferentially in PD-L1(+) tumors, despite considerable uptake in certain normal lymphoid tissues (spleen and lymph nodes) and nonlymphoid tissues (duodenum and brown fat). PD-L1 microSPECT/CT imaging could also distinguish between high and low PD-L1-expressing tumors. The presence of PD-L1(+) immune cells did not compromise tumor uptake of the human PD-L1 antibodies in humanized mice, and we demonstrated that radiotherapy-induced upregulation of PD-L1 expression in murine tumors could be monitored with microSPECT/CT imaging. Together, these data demonstrate that PD-L1 microSPECT/CT is a sensitive technique to detect variations in tumor PD-L1 expression, and in the future, this technique may enable patient selection for PD-1/PD-L1-targeted therapy.

Published
2019

6. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

Author

Lieven Pouillon, P. van Dam, Peter B. Vermeulen, Cecile Colpaert, S. Van Laere, Mark M. Kockx, K. A. Schats, C. Van Berckelaer, François Bertucci, C. Rypens, Luc Dirix, M. Parizel, Wiebren A.A. Tjalma, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Department of Medical Oncology, St-Augustinus, Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Oncology, MESH: Mastectomy, [SDV]Life Sciences [q-bio], CD8-Positive T-Lymphocytes, B7-H1 Antigen, 0302 clinical medicine, MESH: Aged, 80 and over, Surgical oncology, Antineoplastic Combined Chemotherapy Protocols, MESH: B7-H1 Antigen, MESH: Lymphocytes, Tumor-Infiltrating, skin and connective tissue diseases, Mastectomy, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Inflammatory breast cancer (IBC), Immune checkpoint modulators, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, MESH: CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, 3. Good health, MESH: Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, MESH: Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Cohort, Stromal tumour-infiltrating lymphocytes (sTIL), MESH: Inflammatory Breast Neoplasms, Female, Inflammatory Breast Neoplasms, Research Article, Adult, medicine.medical_specialty, Stromal cell, Programmed death-ligand 1 (PD-L1), MESH: Neoadjuvant Therapy, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Inflammatory breast cancer, lcsh:RC254-282, Disease-Free Survival, MESH: Prognosis, 03 medical and health sciences, Immune system, Breast cancer, Lymphocytes, Tumor-Infiltrating, Stroma, Internal medicine, medicine, Adjuvant therapy, Humans, Immune response, Aged, MESH: Humans, business.industry, MESH: Adult, medicine.disease, Survival Analysis, MESH: Disease-Free Survival, Human medicine, Stromal Cells, MESH: Stromal Cells, business, MESH: Female
Abstract

Background Inflammatory breast cancer (IBC) is a rare and rapidly progressive form of invasive breast cancer. The aim of this study was to explore the clinical evolution, stromal tumour-infiltrating lymphocytes (sTIL) infiltration and programmed death-ligand 1 (PD-L1) expression in a large IBC cohort. Patients and methods Data were collected prospectively from patients with IBC as part of an international collaborative effort since 1996. In total, 143 patients with IBC starting treatment between June 1996 and December 2016 were included. Clinicopathological variables were collected, and sTIL were scored by two pathologists on standard H&E stained sections. PD-L1 expression was assessed using a validated PD-L1 (SP142) assay. A validation cohort of 64 patients with IBC was used to test our findings. Results Survival outcomes of IBC remained poor with a 5-year overall survival (OS) of 45.6%. OS was significantly better in patients with primary non-metastatic disease who received taxane-containing (neo)adjuvant therapy (P = 0.01), had a hormone receptor-positive tumour (P = 0.001) and had lower cN stage at diagnosis (P = 0.001). PD-L1 positivity on immune cells (42.9%) was higher in IBC than in non-IBC in both our patient samples and the validation cohort. Furthermore, PD-L1 expression predicted pCR (P = 0.002) and correlated with sTIL infiltration (P

Published
2019

7. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

Author

Hellmann, Matthew, Paz-Ares, Luis, Bernabe Caro, Reyes, Zurawski, Bogdan, Kim, Sang-We, Carcereny Costa, Enric, Park, Keunchil, Alexandru, Aurelia, Lupinacci, Lorena, de La Mora Jimenez, Emmanuel, Sakai, Hiroshi, Albert, Istvan, Vergnenègre, Alain, Peters, Solange, Syrigos, Konstantinos, Barlesi, Fabrice, Reck, Martin, Borghaei, Hossein, Brahmer, Julie, O'Byrne, Kenneth, Geese, William, Bhagavatheeswaran, Prabhu, Rabindran, Sridhar, Kasinathan, Ravi, Nathan, Faith, Ramalingam, Suresh, O’byrne, Kenneth, Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, Bioinformatics Consulting Center, Pennsylvania State University (Penn State), Penn State System-Penn State System, Service de Pathologie respiratoire et allergologie [CHU Limoges], CHU Limoges, Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), National and Kapodistrian University of Athens (NKUA), Assistance Publique - Hôpitaux de Marseille (APHM), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), AstraZeneca, Bristol-Myers Squibb, and Ono Pharmaceutical

Subjects
Oncology, Male, Lung Neoplasms, [SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, B7-H1 Antigen, law.invention, MESH: Ipilimumab, 0302 clinical medicine, Antineoplastic Agents, Immunological, MESH: Aged, 80 and over, Randomized controlled trial, law, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, MESH: B7-H1 Antigen, 030212 general & internal medicine, Response rate (survey), Aged, 80 and over, MESH: Aged, MESH: Middle Aged, General Medicine, Middle Aged, 3. Good health, MESH: Antineoplastic Combined Chemotherapy Protocols, Nivolumab, MESH: Survival Analysis, MESH: Nivolumab, Female, medicine.drug, Adult, medicine.medical_specialty, Ipilimumab, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, 03 medical and health sciences, Internal medicine, Carcinoma, medicine, Humans, Lung cancer, Survival analysis, Aged, MESH: Humans, business.industry, MESH: Adult, medicine.disease, Survival Analysis, MESH: Antineoplastic Agents, Immunological, MESH: Male, respiratory tract diseases, MESH: Lung Neoplasms, Clinical trial, business, MESH: Female, MESH: Carcinoma, Non-Small-Cell Lung
Abstract

[Background] In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC., [Methods] In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more., [Results] Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P=0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy., [Conclusions] First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826. opens in new tab.), Funded by Bristol-Myers Squibb and Ono Pharmaceutical.

Published
2019

8. Awareness of cervical cancer among women attending an HIV treatment centre: a cross-sectional study from Morocco

Author

Herfs, Michaël, Roncarati, Patrick, Koopmansch, Benjamin, Peulen, Olivier, Bruyère, Diane, Lebeau, Alizee, Hendrick, Elodie, Hubert, Pascale, Poncin, Aurelie, Penny, William, Piazzon, Nathalie, Monnien, Franck, Guenat, David, Mougin, Christiane, Pretet, Jean-Luc, Vuitton, Lucine, Segers, Karin, Lambert, Frédéric, Bours, Vincent, De Leval, Laurence, Valmary-Degano, Severine, Quick, Charles, Crum, Christopher, Delvenne, Philippe, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Faculté des sciences et techniques, Université de Kara, Service de Médecine, Hôpital Moulay Hassan ibn Mehdi, Laâyoune, Morocco, Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Centre National de Référence des Papillomavirus (CNRP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA-Research), Université de Liège, Centre Hospitalier Universitaire de Liège (CHU-Liège), GIGA [Université Liège], Immunité et cancer (U932), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Curie [Paris]-Université Paris Descartes - Paris 5 (UPD5), Wellcome Department of Imaging Neuroscience, University College of London [London] (UCL)-Institute of Neurology, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Stanford University, Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Boutin, Marion, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC)

Subjects
MESH: Inflammation, Health Knowledge, Attitudes, Practice, Cross-sectional study, cervical cancer, Uterine Cervical Neoplasms, HIV Infections, MESH: ErbB Receptors, MESH: Anus Neoplasms, 0302 clinical medicine, MESH: Aged, 80 and over, Risk Factors, MESH: Tumor Microenvironment, Surveys and Questionnaires, Obstetrics and Gynaecology, MESH: B7-H1 Antigen, Medicine, awareness, 030212 general & internal medicine, Hiv treatment, MESH: Lymphocytes, Tumor-Infiltrating, ComputingMilieux_MISCELLANEOUS, Early Detection of Cancer, Cervical cancer, MESH: Aged, education.field_of_study, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, MESH: Middle Aged, MESH: Programmed Cell Death 1 Receptor, General Medicine, MESH: Gene Expression Regulation, Neoplastic, 3. Good health, Test (assessment), Morocco, HIV-positive women, 030220 oncology & carcinogenesis, Educational Status, Health education, Female, Papanicolaou Test, Adult, medicine.medical_specialty, HPV, MESH: Mutation, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Precision Medicine, MESH: Prognosis, 03 medical and health sciences, Humans, education, MESH: Kaplan-Meier Estimate, Vaginal Smears, MESH: Humans, business.industry, Research, screening, MESH: Adenocarcinoma, MESH: Adult, medicine.disease, MESH: Male, Increased risk, Cross-Sectional Studies, Social Class, Unemployment, Family medicine, Knowledge test, business, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

ObjectiveTo explore awareness about cervical cancer among Moroccan women attending an HIV treatment centre in Laâyoune city, Morocco.DesignA cross-sectional study was conducted from April to June 2017 using a knowledge test regarding cervical cancer, its risk factors and its prevention.SettingHIV treatment centre at the Hospital of Moulay Hassan Ben Elmehdi in Laâyoune city, Morocco.ParticipantsOne hundred and twenty-three HIV-positive women aged 19 years and older were recruited to this study.ResultsA total of 115 women were eligible to participate in the study. The average age was 34.9±10.2 years. Few women (20%) had heard about cervical cancer and its screening, the majority (17.4%) having received information from mass media. The vast majority (79.1%) of respondents had no knowledge of cervical cancer risk factors, and 80.8% did not know any symptoms of cervical cancer. Only 13% had undergone a Pap smear test. The main reason for not seeking Pap smear was the absence of symptoms (47%).ConclusionOur study documents poor awareness of cervical cancer. Given that the HIV-positive population is at increased risk of cervical cancer, health education programmes should be promoted to increase awareness of cervical cancer as well as access and participation in cervical cancer screening.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results